AnaptysBio, Inc. (ANAB)

Market Cap	618.01M
Revenue (ttm)	57.17M
Net Income (ttm)	-165.66M
Shares Out	30.43M
EPS (ttm)	-6.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	334,405
Open	19.82
Previous Close	19.97
Day's Range	19.58 - 20.58
52-Week Range	13.36 - 41.31
Beta	-0.24
Analysts	Buy
Price Target	54.64 (+169.03%)
Earnings Date	Nov 5, 2024

About ANAB

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and I...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2017
• Employees: 117
• Stock Exchange: NASDAQ
• Ticker Symbol: ANAB
• Website: https://www.anaptysbio.com

Financial Performance

In 2023, AnaptysBio's revenue was $17.16 million, an increase of 66.78% compared to the previous year's $10.29 million. Losses were -$163.62 million, 27.1% more than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for ANAB stock is "Buy." The 12-month stock price forecast is $54.64, which is an increase of 169.03% from the latest price.

Price Target

$54.64

(169.03% upside)

Analyst Consensus: Buy